Kerr, Zimmermann leaving Generation Bio amid restructuring, headcount cuts
Plus: Sáez becomes Agomab’s chief development officer and updates from Forest Road, PDS, enGene and Pyxis
CMO Douglas Kerr and Chief Development Officer Tracy Zimmermann will depart genetic medicine company Generation Bio Co. (NASDAQ:GBIO) as a part of a restructuring in which the company will cut headcount by 40%. Generation Bio plans to focus on its cell targeted lipid nanoparticle delivery technology to develop therapies for extrahepatic cell types and its immune-quiet DNA platform for its lead hemophilia A program and other therapies.
Belgian fibrotic disease company AgomAb Therapeutics N.V. named Andrea Sáez as chief development officer and Angelika Jahreis a director. Founder and former CSO Paolo Michieli and former Chief Development Officer Torsten Dreier will become senior advisers and SAB members. Sáez was COO and CSO at Origo Biopharma S.L., and became head of portfolio at Agomab following its acquisition of Origo in 2021. Jahreis is SVP, development unit head of immunology at Novartis AG (SIX:NOVN; NYSE:NVS)...